Advertisement
Journal of Investigative Dermatology Home

Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in BrafV600E/PtenNULL Mice

Published:September 28, 2021DOI:https://doi.org/10.1016/j.jid.2021.08.434
      Novel therapeutic strategies are required for the effective and lasting treatment of metastatic melanoma, one of the deadliest skin malignancies. In this study, we determined the antimelanoma efficacy of 4′-bromo-resveratrol (4′-BR), which is a small-molecule dual inhibitor of SIRT1 and SIRT3, in a BrafV600E/PtenNULL mouse model that recapitulates human disease, including metastases. Tumors were induced by topical application of 4-hydroxy-tamoxifen on shaved backs of mice aged 10 weeks, and the effects of 4′-BR (5‒30 mg/kg of body weight, intraperitoneally, 3 days per week for 5 weeks) were assessed on melanoma development and progression. We found that 4′-BR at a dose of 30 mg/kg significantly reduced the size and volume of primary melanoma tumors as well as lung metastasis with no adverse effects. Furthermore, mechanistic studies on tumors showed significant modulation in the markers of proliferation, survival, and melanoma progression. Because SIRT1 and SIRT3 are linked to immunomodulation, we performed differential gene expression analysis using a PanCancer Immune Profiling Panel (770 genes). Our data showed that 4′-BR significantly downregulated the genes related to metastasis promotion, chemokine/cytokine regulation, and innate/adaptive immune functions. Overall, inhibition of SIRT1 and SIRT3 by 4′-BR is a promising antimelanoma therapy with antimetastatic and immunomodulatory activities warranting further detailed studies, including clinical investigations.

      Abbreviations:

      4′-BR (4′-bromoresveratrol), 4-HT (4-hydroxytamoxifen), IHC (immunohistochemistry), NAD (nicotinamide adenine dinucleotide), SIRT (sirtuin)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      PDF Download and 24 Hours Online Access
      Society Members (SID/ESDR), remember to log in for access.

      Subscribe:

      Subscribe to Journal of Investigative Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Airoldi I.
        • Di Carlo E.
        • Cocco C.
        • Taverniti G.
        • D'Antuono T.
        • Ognio E.
        • et al.
        Endogenous IL-12 triggers an antiangiogenic program in melanoma cells.
        Proc Natl Acad Sci USA. 2007; 104: 3996-4001
        • Alhazzazi T.Y.
        • Kamarajan P.
        • Verdin E.
        • Kapila Y.L.
        Sirtuin-3 (SIRT3) and the hallmarks of cancer.
        Genes Cancer. 2013; 4: 164-171
        • Arcangeli M.L.
        • Frontera V.
        • Bardin F.
        • Thomassin J.
        • Chetaille B.
        • Adams S.
        • et al.
        The Junctional Adhesion Molecule-B regulates JAM-C-dependent melanoma cell metastasis.
        FEBS Lett. 2012; 586: 4046-4051
        • Azimi A.
        • Pernemalm M.
        • Frostvik Stolt M.
        • Hansson J.
        • Lehtiö J.
        • Egyházi Brage S.
        • et al.
        Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
        Br J Cancer. 2014; 110: 2489-2495
        • Bates M.A.
        • Benninghoff A.D.
        • Gilley K.N.
        • Holian A.
        • Harkema J.R.
        • Pestka J.J.
        Mapping of dynamic transcriptome changes associated with silica-triggered autoimmune pathogenesis in the lupus-prone NZBWF1 mouse.
        Front Immunol. 2019; 10: 632
        • Bisevac J.P.
        • Djukic M.
        • Stanojevic I.
        • Stevanovic I.
        • Mijuskovic Z.
        • Djuric A.
        • et al.
        Association between oxidative stress and melanoma progression.
        J Med Biochem. 2018; 37: 12-20
        • Blattner C.
        • Fleming V.
        • Weber R.
        • Himmelhan B.
        • Altevogt P.
        • Gebhardt C.
        • et al.
        CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions.
        Cancer Res. 2018; 78: 157-167
        • Bogunovic D.
        • O'Neill D.W.
        • Belitskaya-Levy I.
        • Vacic V.
        • Yu Y.L.
        • Adams S.
        • et al.
        Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.
        Proc Natl Acad Sci USA. 2009; 106: 20429-20434
        • Bosch-Presegué L.
        • Vaquero A.
        The dual role of sirtuins in cancer.
        Genes Cancer. 2011; 2: 648-662
        • Botelho N.K.
        • Tschumi B.O.
        • Hubbell J.A.
        • Swartz M.A.
        • Donda A.
        • Romero P.
        Combination of synthetic long peptides and XCL1 fusion proteins results in superior tumor control.
        Front Immunol. 2019; 10: 294
        • Brożyna A.A.
        • Jóźwicki W.
        • Skobowiat C.
        • Jetten A.
        • Slominski A.T.
        RORα and RORγ expression inversely correlates with human melanoma progression.
        Oncotarget. 2016; 7: 63261-63282
        • Chen Y.
        • Sumardika I.W.
        • Tomonobu N.
        • Winarsa Ruma I.M.
        • Kinoshita R.
        • Kondo E.
        • et al.
        Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
        Cancer Lett. 2019; 452: 178-190
        • da Silva W.C.
        • Oshiro T.M.
        • de Sá D.C.
        • Franco D.D.
        • Festa Neto C.
        • Pontillo A.
        Genotyping and differential expression analysis of inflammasome genes in sporadic malignant melanoma reveal novel contribution of CARD8, IL1B and IL18 in melanoma susceptibility and progression.
        Cancer Genet. 2016; 209: 474-480
        • Dankort D.
        • Curley D.P.
        • Cartlidge R.A.
        • Nelson B.
        • Karnezis A.N.
        • Damsky Jr., W.E.
        • et al.
        Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
        Nat Genet. 2009; 41: 544-552
        • Davis I.D.
        • Skak K.
        • Smyth M.J.
        • Kristjansen P.E.
        • Miller D.M.
        • Sivakumar P.V.
        Interleukin-21 signaling: functions in cancer and autoimmunity.
        Clin Cancer Res. 2007; 13: 6926-6932
        • de Andrade L.F.
        • Lu Y.
        • Luoma A.
        • Ito Y.
        • Pan D.
        • Pyrdol J.W.
        • et al.
        Discovery of specialized NK cell populations infiltrating human melanoma metastases.
        JCI Insight. 2019; 4e133103
        • de Oliveira Ada S.
        • Yang L.
        • Echevarria-Lima J.
        • Monteiro R.Q.
        • Rezaie A.R.
        Thrombomodulin modulates cell migration in human melanoma cell lines.
        Melanoma Res. 2014; 24: 11-19
        • de Wit N.J.
        • Rijntjes J.
        • Diepstra J.H.
        • van Kuppevelt T.H.
        • Weidle U.H.
        • Ruiter D.J.
        • et al.
        Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays.
        Br J Cancer. 2005; 92: 2249-2261
        • Denat L.
        • Kadekaro A.L.
        • Marrot L.
        • Leachman S.A.
        • Abdel-Malek Z.A.
        Melanocytes as instigators and victims of oxidative stress.
        J Invest Dermatol. 2014; 134: 1512-1518
        • Eberle J.
        Countering TRAIL resistance in melanoma.
        Cancers (Basel). 2019; 11: 656
        • Edgar R.
        • Domrachev M.
        • Lash A.E.
        Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.
        Nucleic Acids Res. 2002; 30: 207-210
        • Ercolano G.
        • De Cicco P.
        • Rubino V.
        • Terrazzano G.
        • Ruggiero G.
        • Carriero R.
        • et al.
        Knockdown of PTGS2 by CRISPR/CAS9 system designates a new potential gene target for melanoma treatment.
        Front Pharmacol. 2019; 10: 1456
        • Fan J.
        • Lv Z.
        • Yang G.
        • Liao T.T.
        • Xu J.
        • Wu F.
        • et al.
        Retinoic acid receptor-related orphan receptors: critical roles in tumorigenesis.
        Front Immunol. 2018; 9: 1187
        • Flaherty K.T.
        • Infante J.R.
        • Daud A.
        • Gonzalez R.
        • Kefford R.F.
        • Sosman J.
        • et al.
        Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
        N Engl J Med. 2012; 367: 1694-1703
        • Franklin C.
        • Livingstone E.
        • Roesch A.
        • Schilling B.
        • Schadendorf D.
        Immunotherapy in melanoma: recent advances and future directions.
        Eur J Surg Oncol. 2017; 43: 604-611
        • Furuta J.
        • Kaneda A.
        • Umebayashi Y.
        • Otsuka F.
        • Sugimura T.
        • Ushijima T.
        Silencing of the thrombomodulin gene in human malignant melanoma.
        Melanoma Res. 2005; 15: 15-20
        • Gardizi M.
        • Kurschat C.
        • Riese A.
        • Hahn M.
        • Krieg T.
        • Mauch C.
        • et al.
        A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma.
        Arch Dermatol Res. 2012; 304: 397-400
        • George J.
        • Nihal M.
        • Singh C.K.
        • Ahmad N.
        4'-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming.
        Mol Carcinog. 2019; 58: 1876-1885
        • George J.
        • Nihal M.
        • Singh C.K.
        • Zhong W.
        • Liu X.
        • Ahmad N.
        Pro-proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma.
        J Invest Dermatol. 2016; 136: 809-818
        • Ghislin S.
        • Obino D.
        • Middendorp S.
        • Boggetto N.
        • Alcaide-Loridan C.
        • Deshayes F.
        Junctional adhesion molecules are required for melanoma cell lines transendothelial migration in vitro.
        Pigment Cell Melanoma Res. 2011; 24: 504-511
        • González F.E.
        • Ortiz C.
        • Reyes M.
        • Dutzan N.
        • Patel V.
        • Pereda C.
        • et al.
        Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells.
        Immunology. 2014; 142: 396-405
        • Gowrishankar K.
        • Snoyman S.
        • Pupo G.M.
        • Becker T.M.
        • Kefford R.F.
        • Rizos H.
        Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
        J Invest Dermatol. 2012; 132: 1850-1859
        • Hill R.
        • Kalathur R.K.
        • Colaço L.
        • Brandão R.
        • Ugurel S.
        • Futschik M.
        • et al.
        TRIB2 as a biomarker for diagnosis and progression of melanoma.
        Carcinogenesis. 2015; 36: 469-477
        • Hintsala H.R.
        • Jokinen E.
        • Haapasaari K.M.
        • Moza M.
        • Ristimäki A.
        • Soini Y.
        • et al.
        Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.
        Anticancer Res. 2016; 36: 1497-1506
        • Hsu Y.Y.
        • Shi G.Y.
        • Kuo C.H.
        • Liu S.L.
        • Wu C.M.
        • Ma C.Y.
        • et al.
        Thrombomodulin is an ezrin-interacting protein that controls epithelial morphology and promotes collective cell migration.
        FASEB J. 2012; 26: 3440-3452
        • Huang R.
        • Andersen L.M.K.
        • Rofstad E.K.
        Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts.
        J Transl Med. 2017; 15: 203
        • Huang S.
        • Zhang Y.
        • Wang L.
        • Liu W.
        • Xiao L.
        • Lin Q.
        • et al.
        Improved melanoma suppression with target-delivered TRAIL and paclitaxel by a multifunctional nanocarrier.
        J Control Release. 2020; 325: 10-24
        • Jenkins R.W.
        • Fisher D.E.
        Treatment of advanced melanoma in 2020 and beyond.
        J Invest Dermatol. 2021; 141: 23-31
        • Jiang H.
        • Gebhardt C.
        • Umansky L.
        • Beckhove P.
        • Schulze T.J.
        • Utikal J.
        • et al.
        Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
        Int J Cancer. 2015; 136: 2352-2360
        • Jordan K.R.
        • Amaria R.N.
        • Ramirez O.
        • Callihan E.B.
        • Gao D.
        • Borakove M.
        • et al.
        Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
        Cancer Immunol Immunother. 2013; 62: 1711-1722
        • Klarquist J.
        • Tobin K.
        • Farhangi Oskuei P.
        • Henning S.W.
        • Fernandez M.F.
        • Dellacecca E.R.
        • et al.
        CCL22 diverts T regulatory cells and controls the growth of melanoma.
        Cancer Res. 2016; 76: 6230-6240
        • Kong L.Y.
        • Wei J.
        • Sharma A.K.
        • Barr J.
        • Abou-Ghazal M.K.
        • Fokt I.
        • et al.
        A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.
        Cancer Immunol Immunother. 2009; 58: 1023-1032
        • Koroknai V.
        • Szász I.
        • Hernandez-Vargas H.
        • Fernandez-Jimenez N.
        • Cuenin C.
        • Herceg Z.
        • et al.
        DNA hypermethylation is associated with invasive phenotype of malignant melanoma.
        Exp Dermatol. 2020; 29: 39-50
        • Kythreotou A.
        • Siddique A.
        • Mauri F.A.
        • Bower M.
        • Pinato D.J.
        PD-L1.
        J Clin Pathol. 2018; 71: 189-194
        • Lázár-Molnár E.
        • Hegyesi H.
        • Tóth S.
        • Falus A.
        Autocrine and paracrine regulation by cytokines and growth factors in melanoma.
        Cytokine. 2000; 12: 547-554
        • Le Coz V.
        • Zhu C.
        • Devocelle A.
        • Vazquez A.
        • Boucheix C.
        • Azzi S.
        • et al.
        IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.
        Oncotarget. 2016; 7: 82511-82527
        • Lee H.E.
        • Lee J.Y.
        • Yang G.
        • Kang H.C.
        • Cho Y.Y.
        • Lee H.S.
        • et al.
        Inhibition of NLRP3 inflammasome in tumor microenvironment leads to suppression of metastatic potential of cancer cells.
        Sci Rep. 2019; 9: 12277
        • Lenci R.E.
        • Rachakonda P.S.
        • Kubarenko A.V.
        • Weber A.N.
        • Brandt A.
        • Gast A.
        • et al.
        Integrin genes and susceptibility to human melanoma.
        Mutagenesis. 2012; 27: 367-373
        • Li B.
        • Shen W.
        • Peng H.
        • Li Y.
        • Chen F.
        • Zheng L.
        • et al.
        Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT.
        Onco Targets Ther. 2019; 12: 3207-3221
        • Li L.T.
        • Jiang G.
        • Chen Q.
        • Zheng J.N.
        Ki67 is a promising molecular target in the diagnosis of cancer (review).
        Mol Med Rep. 2015; 11: 1566-1572
        • Li M.
        • Zhang B.
        • Sun B.
        • Wang X.
        • Ban X.
        • Sun T.
        • et al.
        A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis.
        J Exp Clin Cancer Res. 2010; 29: 109
        • Liu J.
        • Wang C.
        • Ma X.
        • Tian Y.
        • Wang C.
        • Fu Y.
        • et al.
        High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFβ1.
        J Pathol. 2019; 247: 481-493
        • Luo Y.
        • Robinson S.
        • Fujita J.
        • Siconolfi L.
        • Magidson J.
        • Edwards C.K.
        • et al.
        Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma.
        PLoS One. 2011; 6e20971
        • Marsh Durban V.
        • Deuker M.M.
        • Bosenberg M.W.
        • Phillips W.
        • McMahon M.
        Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
        J Clin Invest. 2013; 123: 5104-5118
        • Martins W.K.
        • Esteves G.H.
        • Almeida O.M.
        • Rezze G.G.
        • Landman G.
        • Marques S.M.
        • et al.
        Gene network analyses point to the importance of human tissue kallikreins in melanoma progression.
        BMC Med Genomics. 2011; 4: 76
        • Mauldin I.S.
        • Wang E.
        • Deacon D.H.
        • Olson W.C.
        • Bao Y.
        • Slingluff Jr., C.L.
        TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
        Int J Cancer. 2015; 137: 1386-1396
        • McKenzie J.A.
        • Grossman D.
        Role of the apoptotic and mitotic regulator survivin in melanoma.
        Anticancer Res. 2012; 32: 397-404
        • Messina J.L.
        • Fenstermacher D.A.
        • Eschrich S.
        • Qu X.
        • Berglund A.E.
        • Lloyd M.C.
        • et al.
        12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?.
        Sci Rep. 2012; 2: 765
        • Michael I.P.
        • Orebrand M.
        • Lima M.
        • Pereira B.
        • Volpert O.
        • Quaggin S.E.
        • et al.
        Angiopoietin-1 deficiency increases tumor metastasis in mice.
        BMC Cancer. 2017; 17: 539
        • Minisini A.M.
        • Pascoletti G.
        • Intersimone D.
        • Poletto E.
        • Driol P.
        • Spizzo R.
        • et al.
        Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma.
        Melanoma Res. 2013; 23: 96-101
        • Monteiro A.C.
        • Muenzner J.K.
        • Andrade F.
        • Rius F.E.
        • Ostalecki C.
        • Geppert C.I.
        • et al.
        Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma.
        Mol Oncol. 2019; 13: 1433-1449
        • Nguyen G.T.
        • Gertz M.
        • Steegborn C.
        Crystal structures of Sirt3 complexes with 4'-bromo-resveratrol reveal binding sites and inhibition mechanism.
        Chem Biol. 2013; 20: 1375-1385
        • Niss Arfelt K.
        • Barington L.
        • Benned-Jensen T.
        • Kubale V.
        • Kovalchuk A.L.
        • Daugvilaite V.
        • et al.
        EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies.
        Blood. 2017; 129: 866-878
        • North B.J.
        • Verdin E.
        Sirtuins: Sir2-related NAD-dependent protein deacetylases.
        Genome Biol. 2004; 5: 224
        • Okamoto M.
        • Liu W.
        • Luo Y.
        • Tanaka A.
        • Cai X.
        • Norris D.A.
        • et al.
        Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta.
        J Biol Chem. 2010; 285: 6477-6488
        • Olbryt M.
        • Habryka A.
        • Tyszkiewicz T.
        • Rusin A.
        • Cichoń T.
        • Jarząb M.
        • et al.
        Melanoma-associated genes, MXI1, FN1, and NME1, are hypoxia responsive in murine and human melanoma cells.
        Melanoma Res. 2011; 21: 417-425
        • Ouyang L.
        • Shen L.Y.
        • Li T.
        • Liu J.
        Inhibition effect of oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo.
        Biomed Res. 2006; 27: 197-202
        • Overwijk W.W.
        • Restifo N.P.
        B16 as a mouse model for human melanoma.
        Curr Protoc Immunol. 2001; (Chapter 20:Unit 20.1)
        • Panza E.
        • De Cicco P.
        • Ercolano G.
        • Armogida C.
        • Scognamiglio G.
        • Anniciello A.M.
        • et al.
        Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival.
        Oncotarget. 2016; 7: 57077-57085
        • Patel S.P.
        • Kurzrock R.
        PD-L1 expression as a predictive biomarker in cancer immunotherapy.
        Mol Cancer Ther. 2015; 14: 847-856
        • Petersen C.C.
        • Diernaes J.E.
        • Skovbo A.
        • Hvid M.
        • Deleuran B.
        • Hokland M.
        Interleukin-21 restrains tumor growth and induces a substantial increase in the number of circulating tumor-specific T cells in a murine model of malignant melanoma.
        Cytokine. 2010; 49: 80-88
        • Pomyje J.
        • Zivný J.H.
        • Stopka T.
        • Simák J.
        • Vanková H.
        • Necas E.
        Angiopoietin-1, angiopoietin-2 and Tie-2 in tumour and non-tumour tissues during growth of experimental melanoma.
        Melanoma Res. 2001; 11: 639-643
        • Purwar R.
        • Schlapbach C.
        • Xiao S.
        • Kang H.S.
        • Elyaman W.
        • Jiang X.
        • et al.
        Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.
        Nat Med. 2012; 18: 1248-1253
        • Qin Y.
        • Verdegaal E.M.
        • Siderius M.
        • Bebelman J.P.
        • Smit M.J.
        • Leurs R.
        • et al.
        Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target.
        Pigment Cell Melanoma Res. 2011; 24: 207-218
        • Ruma I.M.
        • Putranto E.W.
        • Kondo E.
        • Murata H.
        • Watanabe M.
        • Huang P.
        • et al.
        MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.
        Clin Exp Metastasis. 2016; 33: 609-627
        • Sade-Feldman M.
        • Kanterman J.
        • Klieger Y.
        • Ish-Shalom E.
        • Olga M.
        • Saragovi A.
        • et al.
        Clinical significance of circulating CD33+CD11b+HLA–DR– myeloid cells in patients with Stage IV melanoma treated with ipilimumab.
        Clin Cancer Res. 2016; 22: 5661-5672
        • Sajadimajd S.
        • Khazaei M.
        Oxidative stress and cancer: the role of Nrf2.
        Curr Cancer Drug Targets. 2018; 18: 538-557
        • Schats K.A.
        • Van Vré E.A.
        • De Schepper S.
        • Boeckx C.
        • Schrijvers D.M.
        • Waelput W.
        • et al.
        Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
        Histopathology. 2017; 70: 253-263
        • Sebastián C.
        • Satterstrom F.K.
        • Haigis M.C.
        • Mostoslavsky R.
        From sirtuin biology to human diseases: an update.
        J Biol Chem. 2012; 287: 42444-42452
        • Seidl H.
        • Richtig E.
        • Tilz H.
        • Stefan M.
        • Schmidbauer U.
        • Asslaber M.
        • et al.
        Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.
        Hum Pathol. 2007; 38: 768-780
        • Shannon P.
        • Markiel A.
        • Ozier O.
        • Baliga N.S.
        • Wang J.T.
        • Ramage D.
        • et al.
        Cytoscape: a software environment for integrated models of biomolecular interaction networks.
        Genome Res. 2003; 13: 2498-2504
        • Singh C.K.
        • Chhabra G.
        • Ndiaye M.A.
        • Garcia-Peterson L.M.
        • Mack N.J.
        • Ahmad N.
        The role of sirtuins in antioxidant and redox signaling.
        Antioxid Redox Signal. 2018; 28: 643-661
        • Singh C.K.
        • Chhabra G.
        • Ndiaye M.A.
        • Siddiqui I.A.
        • Panackal J.E.
        • Mintie C.A.
        • et al.
        Quercetin-resveratrol combination for prostate cancer management in TRAMP mice.
        Cancers (Basel). 2020; 12: 2141
        • Singh C.K.
        • George J.
        • Chhabra G.
        • Nihal M.
        • Chang H.
        • Ahmad N.
        Genetic manipulation of sirtuin 3 causes alterations of key metabolic regulators in melanoma.
        Front Oncol. 2021; 11: 676077
        • Singh C.K.
        • George J.
        • Nihal M.
        • Sabat G.
        • Kumar R.
        • Ahmad N.
        Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach.
        Oncotarget. 2014; 5: 1987-1999
        • Singh C.K.
        • Panackal J.E.
        • Siddiqui S.
        • Ahmad N.
        • Nihal M.
        Combined inhibition of specific sirtuins as a potential strategy to inhibit melanoma growth.
        Front Oncol. 2020; 10: 591972
        • Slominski A.T.
        • Kim T.K.
        • Takeda Y.
        • Janjetovic Z.
        • Brozyna A.A.
        • Skobowiat C.
        • et al.
        RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D.
        FASEB J. 2014; 28: 2775-2789
        • Stanojevic I.
        • Miller K.
        • Kandolf-Sekulovic L.
        • Mijuskovic Z.
        • Zolotarevski L.
        • Jovic M.
        • et al.
        A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma.
        Int Immunol. 2016; 28: 87-97
        • Su D.M.
        • Zhang Q.
        • Wang X.
        • He P.
        • Zhu Y.J.
        • Zhao J.
        • et al.
        Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy.
        Mol Cancer Ther. 2009; 8: 1292-1304
        • Su S.
        • Ndiaye M.
        • Singh C.K.
        • Ahmad N.
        Mitochondrial sirtuins in skin and skin cancers.
        Photochem Photobiol. 2020; 96: 973-980
        • Sun S.
        • Liu C.
        7α, 25-dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseases.
        Front Pharmacol. 2015; 6: 60
        • Szklarczyk D.
        • Gable A.L.
        • Lyon D.
        • Junge A.
        • Wyder S.
        • Huerta-Cepas J.
        • et al.
        STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.
        Nucleic Acids Res. 2019; 47: D607-D613
        • Terhorst D.
        • Fossum E.
        • Baranska A.
        • Tamoutounour S.
        • Malosse C.
        • Garbani M.
        • et al.
        Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses.
        J Immunol. 2015; 194: 5895-5902
        • Tu Y.
        • Chen C.
        • Fan G.
        Association between the expression of secreted phosphoprotein - related genes and prognosis of human cancer.
        BMC Cancer. 2019; 19: 1230
        • Umansky V.
        • Blattner C.
        • Gebhardt C.
        • Utikal J.
        CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
        Cancer Immunol Immunother. 2017; 66: 1015-1023
        • Vachharajani V.T.
        • Liu T.
        • Wang X.
        • Hoth J.J.
        • Yoza B.K.
        • McCall C.E.
        Sirtuins link inflammation and metabolism.
        J Immunol Res. 2016; 2016: 8167273
        • Vilgelm A.E.
        • Pawlikowski J.S.
        • Liu Y.
        • Hawkins O.E.
        • Davis T.A.
        • Smith J.
        • et al.
        Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.
        Cancer Res. 2015; 75: 181-193
        • Vilgelm A.E.
        • Richmond A.
        Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy.
        Front Immunol. 2019; 10: 333
        • Vitiello M.
        • Evangelista M.
        • Di Lascio N.
        • Kusmic C.
        • Massa A.
        • Orso F.
        • et al.
        Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma.
        Oncogene. 2019; 38: 3756-3762
        • Wagner N.B.
        • Weide B.
        • Gries M.
        • Reith M.
        • Tarnanidis K.
        • Schuermans V.
        • et al.
        Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
        J Immunother Cancer. 2019; 7: 343
        • Wang J.
        • Ding N.
        • Li Y.
        • Cheng H.
        • Wang D.
        • Yang Q.
        • et al.
        Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells.
        Oncotarget. 2015; 6: 20636-20649
        • Wang Y.
        • Su L.
        • Morin M.D.
        • Jones B.T.
        • Mifune Y.
        • Shi H.
        • et al.
        Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.
        Proc Natl Acad Sci USA. 2018; 115: E8698-E8706
        • Wäster P.
        • Orfanidis K.
        • Eriksson I.
        • Rosdahl I.
        • Seifert O.
        • Öllinger K.
        UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-β1-FAP-α.
        Br J Cancer. 2017; 117: 535-544
        • Wilking M.J.
        • Singh C.
        • Nihal M.
        • Zhong W.
        • Ahmad N.
        SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.
        Arch Biochem Biophys. 2014; 563: 94-100
        • Wilking M.J.
        • Singh C.K.
        • Nihal M.
        • Ndiaye M.A.
        • Ahmad N.
        Sirtuin deacetylases: a new target for melanoma management.
        Cell Cycle. 2014; 13: 2821-2826
        • Wong P.F.
        • Wei W.
        • Gupta S.
        • Smithy J.W.
        • Zelterman D.
        • Kluger H.M.
        • et al.
        Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma.
        J Immunother Cancer. 2019; 7: 194
        • Wu X.
        • Giobbie-Hurder A.
        • Liao X.
        • Connelly C.
        • Connolly E.M.
        • Li J.
        • et al.
        Angiopoietin-2 as a biomarker and target for immune checkpoint therapy.
        Cancer Immunol Res. 2017; 5: 17-28
        • Xiong T.F.
        • Pan F.Q.
        • Li D.
        Expression and clinical significance of S100 family genes in patients with melanoma.
        Melanoma Res. 2019; 29: 23-29
        • Xiong T.F.
        • Pan F.Q.
        • Liang Q.
        • Luo R.
        • Li D.
        • Mo H.
        • et al.
        Prognostic value of the expression of chemokines and their receptors in regional lymph nodes of melanoma patients.
        J Cell Mol Med. 2020; 24: 3407-3418
        • Xu Y.
        • Zhang F.
        • Qin L.
        • Miao J.
        • Sheng W.
        • Xie Y.
        • et al.
        Enhanced in-vitro and in-vivo suppression of A375 melanoma by combined IL-24/OSM adenoviral-mediated gene therapy.
        Melanoma Res. 2014; 24: 20-31
        • Zhai Z.
        • Liu W.
        • Kaur M.
        • Luo Y.
        • Domenico J.
        • Samson J.M.
        • et al.
        NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma.
        Oncogene. 2017; 36: 3820-3830
        • Zhang Y.
        • Ertl H.C.
        Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors.
        Oncotarget. 2016; 7: 23282-23299
        • Zhao B.
        • Pritchard J.R.
        Inherited disease genetics improves the identification of cancer-associated genes.
        PLoS Genet. 2016; 12e1006081